The use of tumor necrosis factor inhibitors in patients with rheumatoid arthritis during pregnancy: own observations


DOI: https://dx.doi.org/10.18565/therapy.2019.8.59-66

Trofimov E.A., Mazurov V.I., Gaydukova I.Z.

North-Western State Medical University named after I.I. Mechnikov of the Ministry of Healthcare of Russia, Saint-Petersburg
Pregnancy in patients with rheumatoid arthritis should be planned, since the course of the underlying disease against the background of gestation, as well as its outcomes are fully determined by the activity of the disease and the therapy. The decision on therapy during pregnancy, and especially in the second half of pregnancy, should be based on an assessment of the risk to the child and the expected control of the mother’s disease activity.
To determine the level of RA activity during pregnancy, it is recommended to use the DAS28 CRP index at each visit.
In the analysis of maternal and infant outcomes of gestation, it can be concluded that TNF-alpha inhibitors are low-risk drugs in pregnant women, statistical differences between representatives of this group are not revealed to cause embryotoxic effects.
Keywords: TNF-α inhibitors, pregnancy outcomes, rheumatoid arthritis
Read entire article

Literature


  1. Мазуров В.И., Беляева И.Б., Трофимов Е.А. с соавт. Место генно-инженерных биологических и таргетных препаратов в терапии ревматоидного артрита. Эффективная фармакотерапия. 2019; 15(40): 16–21.

  2. Матьянова Е.В., Кошелева Н.М., Алекберова З.С., Александрова Е.Н. Оценка активности ревматоидного артрита во время беременности и после родов. Научно-практическая ревматология. 2015; 53(2): 155–162.

  3. Кошелева Н.М., Матьянова Е.В. Ревматоидный артрит и беременность. Научно-практическая ревматология. 2014; 52(6): 589–599.

  4. Gotestam Skorpen C., Hoeltzenbein M., Tincani A., Fischer-Betz R., Elefant E., Chambers C. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016; 75: 795–810.

  5. Flint J., Panchal S., Hurrell A., van de Venne M., Gayed M., Schreiber K. et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding – Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. Rheumatology. 2016; 55: 1693–97.

  6. Flint J., Panchal S., Hurrell A. et al. BSR and BHPR guideline on prescribing drugs in pregnancy and breastfeeding-part II: analgesics and other drugs used in rheumatology practice. Rheumatology (Oxford). 2016; 55: 1698–702.

  7. Mirdamadi K., Salinas T., Vali R., Papadimitropoulos M., Piquette-Miller M. Meta-analysis of pregnancy outcomes after exposure to TNF-α Inhibitors during pregnancy for the treatment of arthritic diseases. J Popul Ther Clin Pharmacol. 2018; 25(1): e53–e56.

  8. Ревматология. Фармакотерапия без ошибок: руководство для врачей. Под ред. В.И. Мазурова, О.М. Лесняк. Москва: Е-ното. 2017; 528 с.

  9. Кошелева Н.М. Планирование беременности и наблюдение за беременными с ревматическими заболеваниями. Российские клинические рекомендации. Ревматология. Москва: ГЭОТАР-Медиа. 2017; 380–389 с.

  10. Лила А.М., Трофимов Е.А., Лила В.А. Системная красная волчанка: особенности течения у беременных и варианты терапии. Современная ревматология. 2015; 9(3): 43–47.

  11. Trofimov E., Vasilenko E., Samigullina R., Mazurov V., Gaydukova I. TNF-inhibitors and anti-B- cell treatment in patients with rheumatoid arthritis. Realworld data from the Russian North-western biological treatment cohort. Annals of the Rheumatic Diseases (Annual European Congress of Rheumatology). 2018; 77(2): 1379–80.


About the Autors

Evgeniy A. Trofimov, PhD, associate professor of the Department of therapy, rheumatology, temporary incapacity and medical care quality expertise named after E.E. Eichwald of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 978-86-26. E-mail: Evgeniy.trofimov@szgmu.ru
Vadim I. Mazurov, MD, professor, academician of RAS, head of the Department of therapy, rheumatology, temporary incapacity and medical care quality expertise named after E.E. Eichwald of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia, honored scientist of the Russian Federation. Address: 191015, Saint Petersburg, 41 Kirochnaya Str. Tel.: +7 (921) 951-71-88. E-mail: maz.nwgmu@yandex.ru
Inna Z. Gaydukova, MD, professor of the Department of therapy, rheumatology, temporary incapacity and medical care quality expertise named after E.E. Eichwald of I.I. Mechnikov North-Western State medical University of the Ministry of Healthcare of Russia. 191015, St. Petersburg, 41 Kirochnaya Str. Tel.: +7 (903) 329-03-59. E-mail: ubp1976@list.ru

Back to Content

Бионика Медиа